Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Lalangi Marasinghe, MD

Articles by Lalangi Marasinghe, MD

depression

Clinical Features Associated With Response to Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression

ByJustin Allen, MD,Lalangi Marasinghe, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

March 19th 2025

Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Treatment-Resistant Geriatric Depression: Augmenting or Switching an Antidepressant

ByLalangi Marasinghe, MD,Anvesh Jalasutram, MD,Phil Ryan, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

April 17th 2024

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Latest Updated Articles

Treatment-Resistant Geriatric Depression: Augmenting or Switching an Antidepressant
Published: April 17th 2024 | Updated:
Clinical Features Associated With Response to Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Published: March 19th 2025 | Updated:

Trending on Psychiatric Times

Closing the Gap in Schizophrenia Care: Insights From the INTEGRATE Guidelines

The Importance of Guidelines

Turning Despair into Joy in Music, Psychiatry, and Society

Fostering Resiliency in Mental Health Professionals: A Strengths-Based, Trauma-Informed Framework

© 2025 MJH Life Sciences^®

All rights reserved.